Edwards Lifesciences rises sharply following court action, upgrades The stock is up 13.6% to $82.97 following a U.S. District Court preliminary injunction that limits sales of Medtronic's (MDT) CoreValve system in the United States. JPMorgan and CRT Capital upgraded the name to Neutral and Buy, respectively. Wells Fargo upped its price target to $90 to $91. At current price the next major resistance level is at $86.11, the 52-week high. Support is at $81.93, the opening price of the day.
News For EW From The Last 14 Days
Check below for free stories on EW the last two weeks.
Edwards Lifesciences price target raised to $120 from $95 at Piper Jaffray Piper Jaffray raised its price target for Edwards Lifesciences shares to $120 saying recent Transcatheter Aortic Valve Replacement market momentum is likely to continue. The firm keeps an Overweight rating on the stock.
Edwards Lifesciences price target raised to $114 from $103 at Canaccord Canaccord raised its price target on Edwards Lifesciences to $114 from $103 following positive updates on the SAPIEM franchise and on the heels of several positive trends and upside surprises across the businesses during the quarter. Canaccord maintains its Buy rating on the stock.